NEVVI Medicare utilization intelligence
or

← back

Provider profile

LATTANZI, MICHAEL

Medical Oncology · NPI 1902255276 · AUSTIN, TX

1
Groups
82
Codes · 2024
79,815
Disclosed services

LATTANZI, MICHAEL is a Medical Oncology in AUSTIN, TX, a member of 1 medical group, who billed 82 distinct codes to Medicare Part B in 2024.

Groups: TEXAS ONCOLOGY PA (DALLAS, TX)

Year: 2024 · 2023 · 2022 🔒

Provider overview · all codes · CY2024

79,815
disclosed services
82
codes billed to Medicare Part B
Prior year · CY2023 98,260 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1453 Injection, fosaprepitant, 1 mg
J9271 Injection, pembrolizumab, 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J1756 Injection, iron sucrose, 1 mg
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
J9267 Injection, paclitaxel, 1 mg
Q5129 Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg
J0897 Injection, denosumab, 1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J2469 Injection, palonosetron hcl, 25 mcg
J1626 Injection, granisetron hydrochloride, 100 mcg
80053 Blood test, comprehensive group of blood chemicals
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
83735 Magnesium level
36415 Insertion of needle into vein for collection of blood sample
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
J9045 Injection, carboplatin, 50 mg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J9190 Injection, fluorouracil, 500 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J3475 Injection, magnesium sulfate, per 500 mg
J3480 Injection, potassium chloride, per 2 meq
84443 Blood test, thyroid stimulating hormone (tsh)
J3489 Injection, zoledronic acid, 1 mg
96415 Administration of chemotherapy into vein, each additional hour
96372 Injection of drug or substance under skin or into muscle
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
84153 Psa (prostate specific antigen) measurement, total
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
84403 Testosterone (hormone) level, total
96417 Administration of additional new drug or substance into vein, 1 hour or less
83615 Lactate dehydrogenase (enzyme) level
J1200 Injection, diphenhydramine hcl, up to 50 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
G6015 Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session
J7030 Infusion, normal saline solution , 1000 cc
82784 Gammaglobulin (immune system protein) measurement
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
74177 Ct scan of abdomen and pelvis with contrast
71260 Ct scan of chest with contrast
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
83521 Measurement of immunoglobulin light chains
M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services
J3490 Unclassified drugs
85055 Reticulated (young) platelet measurement
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
85007 Microscopic examination for white blood cells with manual cell count
85027 Complete blood cell count (red cells, white blood cell, platelets), automated test
82728 Ferritin (blood protein) level
83540 Iron level
83550 Iron binding capacity
82232 Beta-2 microglobulin (protein) level
G6013 Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev
85046 Red blood count automated, with additional calculations
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
96523 Irrigation of implanted venous access drug delivery device
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
96361 Infusion into a vein for hydration, each additional hour
96360 Infusion into a vein for hydration, 31-60 minutes
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
96411 Administration of additional new drug or substance into vein using push technique
99231 Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes
81001 Manual urinalysis test with examination using microscope, automated
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
99195 Drawing of blood for a medical problem
71250 Ct scan of chest without contrast
82607 Cyanocobalamin (vitamin b-12) level
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
G6012 Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev
96377 Application of on-body injector for under skin injection
82746 Folic acid level, serum
74176 Ct scan of abdomen and pelvis without contrast
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
70491 Ct scan of soft tissue of neck with contrast

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.